Power Law company profile

Dermapharm

Biotech & Life Sciences · Grünwald, Germany · Founded 1991 · IPO 2018 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$3.65B

Market cap · Apr/2026

Revenue

$1.30B

Latest reported FY

Patent intelligence

$18M patent portfolio · 14 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$18M

0.50% of market cap · 28.4× smaller than top peer ChemoCentryx ($524M)

14 active patent families

Where Dermapharm innovates DiseaseBiomedical engineeringHeating elementHyperthermia TreatmentMaximum temperature

Below peer median on Legal, Strategic, Market, Economic, Technology

Quality vs same-sector peers

Dermapharm on the five Patsnap quality dimensions

Dermapharm in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Dermapharm concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Dermapharm and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Dermapharm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo